Abstract
We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes, TSA reduces chemotactic, pro-Th1 and pro-proliferative mRNAs. A transcriptional imbalance in MS may contribute to immune dysregulation and neurodegeneration, and we identify HDAC inhibition as a transcriptional intervention to ameliorate this imbalance.
Original language | English (US) |
---|---|
Pages (from-to) | 10-21 |
Number of pages | 12 |
Journal | Journal of Neuroimmunology |
Volume | 164 |
Issue number | 1-2 |
DOIs | |
State | Published - Jul 2005 |
Externally published | Yes |
Keywords
- Experimental autoimmune encephalomyelitis
- Histone deacetylase
- Microarrays
- Multiple sclerosis
- Trichostatin A
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology